Listen to the latest hemonc news from international experts
Latest updates on CAR-T therapy for lymphoma
At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for relapsed or refractory (R/R) mantle cell lymphoma, brexucabtagene autoleucel, for R/R follicular lymphoma, axicabtagene ciloleucel, and for some aggressive forms of non-Hodgkin lymphoma, axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel. Despite these approvals, progression of disease and toxicity remain unresolved concerns associated with CAR-T therapy which are currently being investigated.
In this podcast, Caron Jacobson of the Dana-Farber Cancer Institute, Boston, MA, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Frederick Locke of the H. Lee Moffitt Cancer & Research Institute, Tampa, FL, David Miklos of Stanford University, Stanford, CA, Mazyar Shadman of the Fred Hutchinson Cancer Research Center, Seattle, WA, and Sonali Smith of the University of Chicago, Chicago, IL, discuss the latest updates on CAR-T therapy for the treatment of lymphoma.
Date: 16th August 2021